Three-year, RCPSC-accredited training program with extensive clinical exposure across pediatric oncology (leukemia/lymphoma, solid tumor, neuro-oncology, genetics, new agents/innovative therapies), hematology (hemoglobinopathies, marrow failure/MDS, thrombosis/hemostasis, general heme), and bone marrow transplantation & cellular therapy. Training also includes in-depth hematopathology (morphology, flow, cytogenetics, molecular, transfusion/coag) plus adult hematology, radiation oncology, palliative care, electives, continuity clinics, weekly academic half-days, and robust rounds/seminars. Years 1–2 emphasize clinical mastery and forming scholarly projects; Year 3 focuses on scholarship completion, electives, and Transition-to-Practice blocks.
Eligibility Criteria:
-
Canadian/US graduates who have completed at least a 4-year General Pediatrics residency and meet CaRMS eligibility.
-
Sponsored residents from Bahrain, Dominica, Kuwait, Oman, Qatar, Saudi Arabia, UAE, or Libya apply via STARS by emailing [email protected].
Funding Details:
-
Fully funded for all three years (stipend/benefits not itemized).
-
Clinical duties include outpatient/inpatient care and on-call coverage for general hem/onc and BMT/cellular therapy.
Deadline:
-
Canadian/US applicants: follow CaRMS subspecialty timelines.
-
Sponsored residents: January 13, 2026 (for the 3-year fellowship intake).
Where to Go for Further Information:
-
Apply (sponsored residents): [email protected].